RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer

Ke Hui, Shiqi Wu, Yangyang Yue, Yanan Gu, Bing Guan, Xinyang Wang, Jer Tsong Hsieh, Luke S. Chang, Dalin He, Kaijie Wu

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Muscle-invasive or metastatic bladder cancer (BCa) is a life-threatening disease for patients, and tumor angiogenesis is believed to play a critical role in the progression of BCa. However, its underlying mechanism of tumor angiogenesis is still poorly understood. In this study, we discovered that RASAL2, a RAS GTPase activating protein, could inhibit BCa angiogenesis based on our shRNA/siRNA knockdown or ectopic cDNA expression experiments. Mechanistically, RASAL2 downregulation could enhance the phosphorylation of AKT and then subsequently upregulate the expression of ETS1 and VEGFA. Furthermore, there was a negative correlation between RASAL2 and VEGFA or CD31 expression in subcutaneous xenograft and human BCa specimens. Taken together, we provide a new insight into the molecular mechanism of BCa progression, in which RASAL2 can be a new therapeutic target.

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalCellular Signalling
StatePublished - Aug 2018


  • AKT/ETS1 signaling
  • Angiogenesis
  • Bladder cancer
  • RASAL2

ASJC Scopus subject areas

  • Cell Biology


Dive into the research topics of 'RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer'. Together they form a unique fingerprint.

Cite this